United States: FibroBiologics has teamed up with Charles River Laboratories to create cell-based therapies for chronic diseases. They will make special cell banks and a treatment called CYWC628 to help with diabetic foot ulcers. A clinical trial for this treatment is planned to start in 2025.
Specifically, CYWC628 concerns fibroblast base spheroids product.
As reported by the GlobalData, FibroBiologics has completed technology transfer for the existing CGMP manufacturing to Charles River.
FibroBiologics have also produced feasibility studies that endorse the company’s cell manufacturing processes.
The partnership with FibroBiologics builds on Charles River’s broad testing services, which presents a full ‘’conception to cure’’ strategy for advanced therapies.
Charles River Global Manufacturing corporate senior vice-president Kerstin Dolph stated: “The collaboration between Charles River and FibroBiologics is an extension of the ongoing efforts aimed at embracing new-generation regenerative medicine through the deployment of advanced solutions.
“We are delighted to partner with FibroBiologics and to contribute to bring in the market a therapy capable of revolutionizing the treatments for patients with diabetic foot wounds.”
The above agreement means that from now, Charles River will be the sole contract development and manufacturing organisation for FibroBiologics.
FibroBiologics founder and CEO Pete O’Heeron said: The working partnership with Charles River in becoming formally recognised is an essential move to make as we head toward a major wound care RCT in CYWC628 for 2025.
It is exciting that working with Charles River means new opportunities in terms of further innovation and potentially global expansion. By incorporating our innovative therapeutic fibroblast-based spheroids model with Charles River’s experience and outstanding service, we are ready to move forward to bringing this therapy to patients.
FibroBiologics is focused on the application of fibroblasts and fibroblast-derived elements to chronic diseases. This includes multiple sclerosis, wound healing, degenerative disc disease, thymic involution were reversed, psoriasis and cancer.
Charles River inked the deal in June 2024 with Captain T Cell, a German firm, to manufacture plasmid DNA, and retrovirus vectors of gene modified cell therapy.
Source and acknowledgements: ‘FibroBiologics and Charles River link for chronic disease therapies manufacture’ was originally created by Pharmaceutical Technology, a GlobalData owned brand.